Literature DB >> 18558448

Dosimetric analysis of the patterns of local failure observed in patients with locally advanced non-small cell lung cancer treated with neoadjuvant chemotherapy and concurrent conformal (3D-CRT) chemoradiation.

Marta Moreno-Jiménez1, Javier Aristu, José María López-Picazo, Luis Isaac Ramos, Alfonso Gúrpide, Alfonso Gómez-Iturriaga, Jeannete Valero, Rafael Martínez-Monge.   

Abstract

PURPOSE: Three-dimensional conformal radiation therapy (3D-CRT) represents an advance in the better delineation of the target contours and more accurate dose distributions. The purpose of this study was to identify local control prognostic factors in patients with locally advanced non-small cell lung cancer (LA-NSCLC) treated with 3D-CRT.
MATERIAL AND METHODS: Between April 1995 and March 2002, 65 patients (NSCLC stage IIIA: 20%, IIIB: 77%) were treated with cisplatin-based induction and concurrent chemotherapy chemotherapy and hyperfractioned 3D-CRT (1.2Gy b.i.d.; median dose: 72.8 (range: 67-85.9). Clinical parameters (sex, age, performance status, stage, histology, tumor location), therapeutic factors (chemotherapy schedule, 3D-CRT dose, treatment response) and dosimetric factors (volume and dose of GTV, PTV-2, CTV and PTV-1) were evaluated. Local recurrences were divided into three dosimetric categories: those with more than 80% of their volume within high dose region (95% of prescription dose) were considered "central"; those between 20% and 80% were considered "marginal", and those with less than 20% of their volume within high dose region were considered "out-of-field". Local-failure free survival (LFFS) was obtained using the Kaplan-Meier method. Univariate and multivariate analyses were performed.
RESULTS: There were 18 local failures (nine central, eight marginal and one out-of-field). The 2 and 5 year LFFS were 73% and 53%, respectively. In multivariate analysis, PTV-1>1146cc (HR=2.9, CI 95%: 1.1-7.5, p=0.026) was the only factor associated with worse LFFS.
CONCLUSIONS: This study shows that local control was independently related to PTV-1 size. The great majority of local recurrences were located in the high-dose region. Dosimetric parameters may contribute to improving radiotherapy results in multidisciplinary treatment for LA-NSCLC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18558448     DOI: 10.1016/j.radonc.2008.05.019

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105.

Authors:  Joseph K Salama; Thomas E Stinchcombe; Lin Gu; Xiaofei Wang; Karen Morano; Jeffrey A Bogart; Jeffrey C Crawford; Mark A Socinski; A William Blackstock; Everett E Vokes
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-07       Impact factor: 7.038

2.  CT-guided implantation of radioactive 125I seed in advanced non-small-cell lung cancer after failure of first-line chemotherapy.

Authors:  Tao Zhang; Mingjian Lu; Sheng Peng; Weidong Zhang; Guang Yang; Zhenyin Liu; Sristi Singh; Yadi Yang; Fujun Zhang; Fei Gao
Journal:  J Cancer Res Clin Oncol       Date:  2014-04-11       Impact factor: 4.553

3.  Multidisciplinary collaborative gross tumour volume definition for lung cancer radiotherapy: a prospective study.

Authors:  Abigail E Hollingdale; Tom W Roques; John Curtin; W M Craig Martin; Gail Horan; Ann Barrett
Journal:  Cancer Imaging       Date:  2011-12-07       Impact factor: 3.909

4.  The Clinical Value of Computed Tomography (CT)-Guided 125I Brachytherapy for Locally Advanced Non-Small Cell Lung Cancer After Progression of Concurrent Radiochemotherapy.

Authors:  Zhanwang Xiang; Zhihui Zhong; Luwen Mu; Guohong Li; Churen Zhou; Haofan Wang; Mingsheng Huang
Journal:  Cancer Manag Res       Date:  2021-07-05       Impact factor: 3.989

5.  Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer.

Authors:  Sana D Karam; Zachary D Horne; Robert L Hong; Don McRae; David Duhamel; Nadim M Nasr
Journal:  Radiat Oncol       Date:  2013-07-10       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.